Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kalaris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kalaris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vandekop Amy O'Leary | VP, Corporate Controller | – | Aug 28, 2026 | 1 |
| Keating Laurie | Director | – | Aug 3, 2026 | 1 |
| Bayko Liisa Ann | Chief Financial Officer | – | Jul 20, 2026 | 1 |
| Patterson Leone D | Director | – | Jun 4, 2026 | 1 |
| Akkaraju Srinivas | Director | 19,408Indirect | Jun 4, 2026 | 4 |
| Adamis Anthony P | Director | – | Jun 4, 2026 | 1 |
| Hallal David | Director | 2,143,662 | Jun 4, 2026 | 1 |
| Jovan-Embiricos Morana | Director | 100,197 | Jun 4, 2026 | 1 |
| Dybbs Michael | Director | – | Jun 4, 2026 | 1 |
| Ferrara Napoleone | Director | 504,000 | Jun 4, 2026 | 1 |
| Samsara BioCapital, L.P. | 10% Owner | 19,408Indirect | May 22, 2026 | 2 |
| Samsara BioCapital GP, LLC | 10% Owner | 19,408Indirect | May 22, 2026 | 2 |
| Samsara Opportunity Fund, L.P. | 10% Owner | 19,408Indirect | May 22, 2026 | 3 |
| Samsara Opportunity Fund GP, LLC | 10% Owner | 19,408Indirect | May 22, 2026 | 3 |
| Hagen Brett R | Chief Accounting Officer | 0 | Mar 23, 2026 | 1 |
| Feinsod Matthew | Chief Medical Officer | 4,030 | Mar 20, 2026 | 1 |
| Oxtoby Andrew | See Remarks | – | Mar 20, 2026 | 1 |
| Gall Matthew | Chief Financial Officer | – | Mar 20, 2026 | 2 |
| Patel Samir Chandrakant | Director | 100,800Indirect | Apr 11, 2025 | 0 |
| Sinha Vikas | See Remarks | 49,129 | Feb 24, 2025 | 0 |
| Miller Edward | General Counsel | 6,517 | Feb 24, 2025 | 0 |
| Brainard Diana | Chief Executive Officer | 723,363 | Nov 20, 2024 | 0 |
| Bornstein Jeffrey S | Director | 110,197 | Jun 7, 2024 | 0 |
| Tomasello Shawn | Director | 70,000 | Jun 7, 2024 | 0 |
| Vera Juan | Director | 2,409,928 | Jun 7, 2024 | 0 |
| Brenner Malcolm | Director | 100,197 | Jun 7, 2024 | 0 |
| Adams Derek N. | Director | 70,000 | Jun 7, 2024 | 0 |
| Piccina Cintia | Chief Commercial Officer | 147,000 | Jul 5, 2023 | 0 |
| Gilead Sciences, Inc. | 10% Owner | 16,635,286 | Jun 28, 2023 | 0 |
| Leen Ann M. | Chief Scientific Officer | 124,006 | Feb 3, 2023 | 0 |
| Van Beek Jeroen B | Chief Commercial Officer | 333,726 | Nov 18, 2022 | 0 |
| Atillasoy Ercem | See Remarks | 131,372 | Oct 26, 2022 | 0 |
| Gadicke Ansbert | Director, 10% Owner | 16,674,766Indirect | Aug 1, 2022 | 0 |
| ElevateBio, LLC | Director, 10% Owner | 16,674,766 | Aug 1, 2022 | 0 |
| Melian Agustin | Chief Medical Officer | 453,529 | Oct 5, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2025 (view filing)4:15 PM ET | Jan 10 | 3 days | Sinha VikasSee Remarks | SSale | −979 | $0.4401 | −$430.86 | −0.1%1.14M after | |
| Jan 13, 2025 (view filing)4:15 PM ET | Jan 10 | 3 days | Hagen Brett RChief Accounting Officer | SSale | −332 | $0.4401 | −$146.11 | −0.5%68.2K after | |
| Jan 13, 2025 (view filing)4:15 PM ET | Jan 10 | 3 days | Miller EdwardGeneral Counsel | SSale | −409 | $0.4401 | −$180 | −0.3%153.5K after | |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Sinha VikasSee Remarks | SSale | −129 | $9.50 | −$1.23K | −0.3%49.4K after | 2 lots |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Hagen Brett RChief Accounting Officer | SSale | −36 | $9.50 | −$342.16 | −1.2%2.93K after | 2 lots |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Miller EdwardGeneral Counsel | SSale | −52 | $9.50 | −$493.85 | −0.8%6.62K after | 2 lots |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Miller EdwardGeneral Counsel | SSale | −106 | $10.08 | −$1.07K | −1.6%6.52K after | |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Hagen Brett RChief Accounting Officer | SSale | −96 | $10.08 | −$967.68 | −3.3%2.83K after | |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Sinha VikasSee Remarks | SSale | −303 | $10.08 | −$3.05K | −0.6%49.1K after | |
| Mar 27, 2025 (view filing) | Mar 26 | 1 day | Hagen Brett RChief Accounting Officer | SSale | −907 | $8.97 | −$8.14K | −32.0%1.93K after | |
| Feb 17, 2026 (view filing)8:15 PM ET | Dec 18, 2025 | 61 daysLate | Akkaraju Srinivas and 4 othersDirector, 10% Owner | PPurchase | +479.8K | $10.42 | +$5.00M | +32.0%1.98M after | |
| Mar 23, 2026 (view filing) | Mar 20 | 3 days | Hagen Brett RChief Accounting Officer | SSale | −1.92K | $6.72 | −$12.9K | −100.0%0 after | |
| May 22, 2026 (view filing)7:47 PM ET | May 20 | 2 days | Akkaraju Srinivas and 4 othersDirector, 10% Owner | PPurchase | +244.3K | $4.83 | +$1.18M | +12.3%2.22M after |